← Back to Screener
Curis Inc (CRIS)
Price$0.59
Favorite Metrics
Price vs S&P 500 (26W)-61.73%
Price vs S&P 500 (4W)-22.35%
Market Capitalization$27.91M
All Metrics
Book Value / Share (Quarterly)$0.42
P/TBV (Annual)4.90x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.41%
Cash Flow / Share (Quarterly)$-2.10
Price vs S&P 500 (YTD)-33.50%
Gross Margin (TTM)99.52%
Net Profit Margin (TTM)-80.29%
EPS (TTM)$-1.20
10-Day Avg Trading Volume1.06M
EPS Excl Extra (TTM)$-1.20
Revenue Growth (5Y)-2.72%
EPS (Annual)$-0.58
ROI (Annual)-138.81%
Gross Margin (Annual)99.52%
Net Profit Margin (5Y Avg)-387.11%
Cash / Share (Quarterly)$0.39
Revenue Growth QoQ (YoY)-65.98%
ROA (Last FY)-37.97%
Revenue Growth TTM (YoY)-13.43%
EBITD / Share (TTM)$-0.59
ROE (5Y Avg)-114.89%
Operating Margin (TTM)-60.50%
Cash Flow / Share (Annual)$-2.10
P/B Ratio5.11x
P/B Ratio (Quarterly)2.34x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)2.42x
Net Interest Coverage (TTM)-177.56x
ROA (TTM)-26.11%
EV / EBITDA (TTM)9.21x
EPS Incl Extra (Annual)$-0.58
Current Ratio (Annual)0.49x
Quick Ratio (Quarterly)0.36x
3-Month Avg Trading Volume0.51M
52-Week Price Return-46.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$69.20
P/S Ratio (Annual)2.96x
Asset Turnover (Annual)0.47x
52-Week High$3.13
Operating Margin (5Y Avg)-371.89%
EPS Excl Extra (Annual)$-0.58
Tangible BV CAGR (5Y)-25.67%
26-Week Price Return-57.75%
Quick Ratio (Annual)0.36x
13-Week Price Return-25.60%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.49x
Enterprise Value$22.844
Revenue / Share Growth (5Y)-30.62%
Asset Turnover (TTM)0.33x
Book Value / Share Growth (5Y)-51.03%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)-80.29%
Cash / Share (Annual)$0.39
3-Month Return Std Dev98.43%
Gross Margin (5Y Avg)97.81%
Net Income / Employee (TTM)$-0
ROE (Last FY)-138.81%
Net Interest Coverage (Annual)-9.23x
EPS Basic Excl Extra (Annual)$-0.58
P/FCF (TTM)139.53x
Receivables Turnover (TTM)5.64x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.20
Receivables Turnover (Annual)5.64x
ROI (TTM)354.38%
P/S Ratio (TTM)2.96x
Pretax Margin (5Y Avg)-387.11%
Revenue / Share (Annual)$0.72
Tangible BV / Share (Annual)$76.00
Price vs S&P 500 (52W)-76.77%
Year-to-Date Return-30.86%
5-Day Price Return34.22%
EPS Normalized (Annual)$-0.58
ROA (5Y Avg)-56.91%
Net Profit Margin (Annual)-80.29%
Month-to-Date Return24.45%
Cash Flow / Share (TTM)$-9.25
EBITD / Share (Annual)$-0.59
Operating Margin (Annual)-60.50%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-81.88%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.20
P/TBV (Quarterly)1.91x
P/B Ratio (Annual)2.34x
Inventory Turnover (TTM)0.00x
Pretax Margin (TTM)-80.29%
Book Value / Share (Annual)$0.42
Price vs S&P 500 (13W)-26.29%
Beta3.62x
Revenue / Share (TTM)$0.60
ROE (TTM)354.38%
52-Week Low$0.49
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.10
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CRISCuris Inc | 2.96x | -13.43% | 99.52% | — | $0.59 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Curis is a biotechnology company developing immuno-oncology and precision oncology therapies targeting solid tumors, diffuse large B-cell lymphoma, and hematological cancers. The company's pipeline includes five drug candidates: Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.